<- Go Home
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Market Cap
$208.2M
Volume
1.3M
Cash and Equivalents
$46.7M
EBITDA
-$57.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.06
52 Week Low
$0.63
Dividend
N/A
Price / Book Value
10.16
Price / Earnings
-2.61
Price / Tangible Book Value
10.16
Enterprise Value
$182.9M
Enterprise Value / EBITDA
-3.24
Operating Income
-$57.2M
Return on Equity
260.65%
Return on Assets
-41.97
Cash and Short Term Investments
$82.6M
Debt
$57.2M
Equity
$20.5M
Revenue
N/A
Unlevered FCF
-$23.9M
Sector
Pharmaceuticals
Category
N/A